secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-08-06T20:01:56+00:00
Accession:  0001628280-26-054264
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q2 revenue $11.4M (+1.7% YoY); maintains FY2026 guidance $54-57M
-------------------------------------------------------------------------

- Revenue from TriNav system $11.4M, up 1.7% YoY; gross margin improved to 86.8% from 83.9%.
- Operating loss widened to $9.8M from $7.3M YoY on higher sales and marketing spend.
- Net loss $9.2M ($0.16 loss per share) vs $9.0M ($0.27 loss per share) in Q2 2025.
- Cash and equivalents $46.3M after $46.0M equity offering in Q1; runway sufficient for expansion.
- CMS established G-code for reimbursement of pressure-generating catheter in office-based labs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/0001628280-26-054264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/tlsi-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-054264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer